Survey: U.S. neurologists would prescribe Leqembi if fully approved
By
Alicia Lasek
Apr 12, 2023
A “healthy proportion” of surveyed neurologists have already begun prescribing the treatment, and nearly all said they planned to do so if traditional FDA approval is granted.
Alzheimer’s blood biomarkers not ready for primary care use, expert panel decides
By
Alicia Lasek
Aug 18, 2022
An international group of clinicians and researchers have agreed that Alzheimer’s disease blood biomarkers are a significant breakthrough, but are not yet ready for general clinical and primary care...
U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
Low-dose brain radiation improves behavior, cognition in Alzheimer’s pilot study
By
Alicia Lasek
May 04, 2021
Low-dose ionizing radiation may be a promising, although possibly controversial, therapy for Alzheimer’s disease, according to the researchers behind a small new pilot study.